We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
UFS
201
DELISTED
DOMTAR CORPORATION (New)
UFS
| $17.4M | 0.12% |
+315,996
| New | +$15.3M |
|
202
Trex
TREX
$4.51B
| $17.4M | 0.12% |
169,907
+21,235
| +14% | +$2.14M |
|
|
FRTA
203
DELISTED
Forterra, Inc
FRTA
| $17.3M | 0.12% |
+734,897
| New | +$17.2M |
|
|
PFPT
204
DELISTED
Proofpoint, Inc.
PFPT
| $17.2M | 0.12% |
+98,981
| New | +$16.1M |
|
205
ICICI Bank
IBN
$106B
| $17.1M | 0.12% |
1,001,321
+21,880
| +2% | +$364K |
|
206
CEVA Inc
CEVA
$1.01B
| $17.1M | 0.12% |
360,869
+61,178
| +20% | +$3.02M |
|
207
Masco
MAS
$16B
| $17M | 0.12% |
288,854
-352,975
| -55% | -$21.8M |
|
208
IBM
IBM
$202B
| $16.8M | 0.12% |
120,163
-6,186
| -5% | -$846K |
|
209
Ally Financial
ALLY
$13.1B
| $16.6M | 0.11% |
333,287
+138,840
| +71% | +$7.13M |
|
210
Norfolk Southern
NSC
$78.8B
| $16.4M | 0.11% |
61,855
+25,786
| +71% | +$7.12M |
|
211
Zymeworks
ZYME
$1.68B
| $16.4M | 0.11% |
473,124
+111,583
| +31% | +$3.54M |
|
212
SLB Ltd
SLB
$77.8B
| $16.4M | 0.11% |
511,775
-21,167
| -4% | -$650K |
|
213
Intellia Therapeutics
NTLA
$1.5B
| $16.4M | 0.11% |
101,127
-81,790
| -45% | -$6.37M |
|
214
MacroGenics
MGNX
$235M
| $16.3M | 0.11% |
608,523
-67,607
| -10% | -$1.98M |
|
215
Weyerhaeuser
WY
$17.3B
| $16.3M | 0.11% |
472,721
+352,021
| +292% | +$13.1M |
|
216
Arrowhead Research
ARWR
$12.1B
| $16.3M | 0.11% |
196,408
+32,450
| +20% | +$2.42M |
|
|
IMGN
217
DELISTED
Immunogen Inc
IMGN
| $16.2M | 0.11% |
+2,461,459
| New | +$17.2M |
|
218
PPG Industries
PPG
$25.9B
| $16M | 0.11% |
94,042
+60,653
| +182% | +$10.4M |
|
219
DuPont de Nemours
DD
$18.6B
| $15.7M | 0.11% |
161,934
+106,483
| +192% | +$10.7M |
|
220
Vail Resorts
MTN
$5.19B
| $15.6M | 0.11% |
49,357
+48,611
| +6,516% | +$15.5M |
|
|
DRNA
221
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $15.6M | 0.11% |
418,245
-990,748
| -70% | -$30.4M |
|
222
Becton Dickinson
BDX
$43.1B
| $15.6M | 0.11% |
65,718
+21,597
| +49% | +$5.18M |
|
223
Cogent Biosciences
COGT
$6.79B
| $15.5M | 0.11% |
1,910,720
+1,435,911
| +302% | +$12.1M |
|
224
AstraZeneca
AZN
$263B
| $15.4M | 0.11% |
128,693
+46,901
| +57% | +$5.15M |
|
|
TCRR
225
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $15.3M | 0.11% |
934,551
+540,263
| +137% | +$10.9M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.